Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature.
Amiodarone-induced thyrotoxicosis (AIT) is a well-known complication of amiodarone treatment found in 3% to 12% of patients. Two types of AIT have been described, each associated with a distinct histologic pattern of thyroid involvement. Type 1, which typically develops in the background of pre-existing thyroid disease, is due to iodine-induced excess thyroid hormone synthesis, whereas type 2 is due to destructive thyroiditis. The prevalence of thyroid cancer in patients with AIT is unknown. We report a case of papillary thyroid carcinoma associated with type 2 AIT.
Saad
Aly
A
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0529, USA.
Falciglia
Mercedes
M
Steward
David L
DL
Nikiforov
Yuri E
YE
D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D018265:Carcinoma, Papillary, Follicular / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009154:Mutation; D013964:Thyroid Neoplasms / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D013971:Thyrotoxicosis / Q000139:chemically induced / Q000150:complications / Q000473:pathology*
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone